

Medrxiv SNOMED-POIG

1 **Standardising the structure of routinely collected data for childhood ocular inflammation: a**
2 **SNOMED-CT mapping project**

3

4 **Salomey Kellett¹, Ameenat Lola Solebo^{1,2,3*}, on behalf of the Paediatric Ocular Inflammation**
5 **UNICORN Study Group[¶]**

6 1. Population, Policy and Practice Programme, UCL GOS Institute of Child Health, London,
7 UK

8 2. National Institute for Health Research Biomedical Research Centre at UCL Great
9 Ormond Street Institute of Child Health and Great Ormond Street Hospital, London UK

10 3. Great Ormond Street Hospital for Children NHS Trust, London UK

11

12 *Corresponding author

13 Email: a.solebo@ucl.ac.uk

14

15 [¶]Membership of the Paediatric Ocular Inflammation UNICORN Study Group in provided in

16 Acknowledgements

17

18

19

20

Medrxiv SNOMED-POIG

21 **Abstract**

22 **Background and aims**

23 Multicentre, longitudinal research methods are usually necessary for rare disease research. SNOMED
24 CT (Systematized Nomenclature of Medicine Clinical Terms), the comprehensive and standardized
25 terminology system can be used to enhance the interoperability of data collected across different
26 settings. Childhood uveitis is a rare, blinding disorder, with uncertainties around disease distribution
27 and outcome. To enhance the interoperability of uveitis data, we created a SNOMED CT coded
28 dataset derived from a core clinical dataset.

29 **Methods**

30 Data elements were selected from a published list developed through a consensus exercise undertaken
31 by a national disease research group, the United Kingdom's Paediatric Ocular Inflammatory Group
32 (POIG). Items were organised using a three level priority score, based on the National Institute for
33 Health (NIH) model for common data elements, and grouped using the Health Level 7 (HL7) standard
34 "Fast Healthcare Interoperability Resources" (FHIR) generic data structure, and then mapped across
35 to the SNOMED CT codes.

36 **Results**

37 From the POIG consensus exercise, 160 elements were selected: 89 as high priority items, with 35 as
38 medium and 29 as low priority items. These elements, and response items where appropriate, were
39 grouped into Patient (n= 13 items), Observation (n= 63 items), Condition (n= 20 items), Procedure
40 (n= 44 items), Medication (n= 18 items). There were four items for which a SNOMED CT ID could
41 not be found.

42 **Conclusion**

43 Through this mapping activity, using international coding and terminologies, we have created a
44 dataset for childhood onset uveitis care and research. This dataset provides a standardised vocabulary
45 for describing clinical concepts, with a semantic interoperability which will support the exchange of
46 data across different systems, organizations, and international or supranational groups. Future

Medrxiv SNOMED-POIG

47 expansion of the dataset will be needed to ensure coverage of international concepts and care
48 structures.

49

50 **Author summary**

51 Through a mapping activity, in which data items from a consensus developed core clinical dataset
52 were mapped across to SNOMED CT terminologies, we have created a dataset for childhood onset
53 uveitis care and research. This dataset provides a standardised vocabulary for describing clinical
54 concepts, with a semantic interoperability which will support the exchange of data across different
55 systems, organizations, and international or supranational groups.

56

57 **Introduction**

58 Childhood uveitis comprises a group of individually rare inflammatory disorders which exhibit
59 different clinical ocular and systemic phenotypes,(1) and confer a life-long risk of risk of visual
60 morbidity.(2,3) In up to 25% of children with uveitis, a degree of permanent vision loss will affect at
61 least one eye,(4) and the disease, and attendant risk of further visual loss, often persists into mid-
62 adulthood.(5) Prompt diagnosis and prompt disease control are key in preventing uveitic blindness.
63 Achieving this control necessitates a combination of topical and systemic corticosteroids, systemic
64 disease-modifying immunomodulatory agents, and biologic therapies, with agents typically chosen in
65 a trial and error approach. Alongside the need to personalise therapeutic approach, other evidence
66 gaps in the field include aetiology, with the majority of cases being idiopathic,(6) disease burden, with
67 studies reporting a 20-fold difference in incidence rates,(6–8) and the uncertainty around the
68 determinants of long term positive and negative eye and global health outcomes.(9,10)

69

70 Routinely collected clinical data have been harnessed across different disease areas to enable
71 observational research on disease incidence,(11) prognostication,(12) and to support interventional
72 studies.(13) For rare diseases, where multi-centre work is needed to reach the sample sizes sufficient
73 to undertake such research, the re-use of routinely collected clinical data is dependent on the

Medrxiv SNOMED-POIG

74 interoperability of data extracted across different sites.(14) Several groups have developed approaches
75 and resources with the aim of defining standardized datasets for the systematic collection of uveitis-
76 related information.(15–17) However, while these represent important advances, more is needed to
77 support interoperability, specifically, the common data elements within the developed datasets must
78 be supported by coding derived from a clearly structured terminology standard.

79

80 The SNOMED CT (Systematized Nomenclature of Medicine Clinical Terms) is a comprehensive and
81 standardized terminology system widely used in healthcare and research.(18) To enhance the
82 interoperability of uveitis data, we created a SNOMED CT coded dataset derived from a core clinical
83 dataset, developed in collaboration with the United Kingdom’s Paediatric Ocular Inflammation Group
84 (POIG).(15,19) We present an overview of the dataset and its development process.

85

86 **Methods**

87 We undertook the development of a dataset which used an international terminology (SNOMED CT)
88 to support interoperability.

89

90 **Selection of data elements**

91 The POIG core clinical dataset for non-infectious uveitis was used as a source of data elements for
92 this mapping exercise. POIG is a multi-disciplinary group formed of clinicians who manage children
93 with complex inflammatory disorders, with a central aim of delivering the evidence base needed to
94 support the care of these children, and supporting the translation of that evidence base into changes in
95 policy and practice. The group developed, through Delphi consensus, as reported elsewhere,(15) a
96 consensus dataset for the routine collection of data for children diagnosed with uveitis. This dataset
97 includes common data items (CDEs) on demographic details, pathways to diagnosis, ocular disease
98 phenotype, activity level and severity scores, the presence, type and severity of co-existent systemic
99 disease, clinical interventions, and laboratory and imaging findings. Those data items which formed
100 the POIG core clinical dataset (having been agreed upon through the consensus exercise) were

Medrxiv SNOMED-POIG

101 selected. Other items, which had been suggested within the ‘long-list’ developed by the Delphi group,
102 were also selected (table 1). These were judged to be ‘low priority’ items, versus the ‘high priority’
103 items comprising the core clinical dataset. Those items which were agreed upon by the majority of the
104 Delphi group, but which had not reached the threshold for formal inclusion in the core clinical dataset
105 (table 1), were coded as ‘moderate priority’. This three level prioritisation scoring was based on the
106 National Institute for Health (NIH) model for common data elements (CDEs) (table 1).(20)
107
108

Medrxiv SNOMED-POIG

109 **Table 1 Prioritisation of data elements**

Priority	NIH classification(20)	Definition
High	General core/disease core*	Items included in the core childhood uveitis clinical dataset following consensus decision by Delphi group, ie inclusion supported by >95%
Moderate	Supplemental—highly recommended	Items supported by majority of Delphi group (>50%) but not reaching consensus threshold for inclusion in core dataset
Low	Supplemental or Exploratory	Items supported by less than or equal to 50% of the Delphi group

110

111 **Standardisation**

112 The selected data elements were mapped to the SNOMED CT terminologies. The June 2022 release
113 of SNOMED CT, which has over 350K active concepts, each with single or multiple synonymous
114 human readable descriptions, was used. These concepts are interrelated in order to provide additional
115 definition or context, with relationships being either hierarchical (eg with “clinical finding” being
116 higher in a hierarchical relationship with “visual acuity”) or non-hierarchical (e.g. “associated
117 findings”, or with “viral uveitis” having a defining relationship between “is a type” and “infective
118 uveitis”).

119

120 In order to further support interoperability, two additional international standards and terminologies
121 were used. Diagnoses were mapped to the International Statistical Classification of Diseases and
122 Related Health Problems, 10th revision (ICD10). Terms were grouped using the Heath Level 7 (HL7)
123 standard "Fast Healthcare Interoperability Resources" (FHIR) generic data structures into Patient,
124 Observation, Condition, Procedure, Medication. (21)

125

126 **Results**

Medrxiv SNOMED-POIG

127 From the POIG consensus exercise, 160 elements were selected: 89 as high priority items, with 35 as
128 medium and 29 as low priority items. These elements, and response items where appropriate, were
129 grouped into Patient (n= 13 items), Observation (n= 63 items), Condition (n= 20 items), Procedure
130 (n= 44 items), Medication (n= 18 items). SNOMED CT provided IDs which differentiated between
131 concepts such as procedures and findings, and enables anchoring in eye laterality. For example,
132 separate codes were identified for the capture of related but different concepts such as ‘measurement
133 of visual acuity’ (procedure), ‘measured distance visual acuity’ (finding), ‘measured visual acuity in
134 right eye’ (finding), ‘measured visual acuity in left eye’ (finding).

135

136 There were four items for which a SNOMED CT ID could not be found: (i) laser photometry or laser
137 flare photometry, a procedure in which light scatter is measured to quantify anterior ocular chamber
138 inflammation; (ii) laser flare photometry results, measured in photos per microseconds; vitreous haze
139 grade, a measure of the degree of inflammatory change seen in the vitreous cavity of the eye using
140 obscuration of retinal details seen; and (iv) macular thickness as measured using optical coherence
141 tomography. Data elements, response options and associated values can be found via an online
142 repository (DOI: 10.5522/04/24434278).

143

144 **Discussion**

145 Through this mapping activity, using international coding and terminologies, we have created a
146 dataset for childhood onset uveitis care and research. This dataset provides a standardised vocabulary
147 for describing clinical concepts, with a semantic interoperability which will support the exchange of
148 data across different systems, organizations, and international or supranational groups.

149

150 Clinical research into rare disorders, such as childhood uveitis, faces the common challenge of
151 securing sample sizes sufficiently large as to support robust statistical analysis. This challenge is
152 typically addressed through multi-centre studies.(14) The sharing and harmonisation of data across
153 different centres is dependent on interoperability of collected datasets. with the aim of facilitating

Medrxiv SNOMED-POIG

154 routine and standardized data collection. This is particularly timely for childhood uveitis. Although a
155 rare condition, there is evidence that previous studies have underestimated disease incidence.
156 Dependent on study setting and year of study, disease incidence estimates now range from 1 to 101
157 cases per 100,000 children,(6,8) with evidence of rising incidence,(6) and evidence of a higher than
158 expected incidence during and following the COVID-19 pandemic.(22,23) However, the potential
159 benefit of this standardised dataset go beyond this rare disease. The items within the UK's Royal
160 College of Ophthalmologists recommended dataset for clinical care for adult inflammatory
161 disease(17) are represented within the data items selected for mapping, having been used in the
162 original consensus work undertaken by the Paediatric Ocular Inflammation Group (POIG). This
163 demonstrates the utility of this dataset for adult onset disease. Adult uveitis is one of the commonest
164 reasons for attendance at eye emergency services, and also an important cause of working age
165 blindness.(2)

166

167 The potential beneficial impact of this dataset on patient care and research is dependent on its use
168 within clinical and research communities. Facilitators for the future implementation of the dataset
169 include the involvement of a national organisation, specifically POIG, in its development, the
170 harmonisation with the RCOphth's national dataset, the call for such activities from international
171 organisations including the disease specific Multinational Interdisciplinary Working Group for
172 Uveitis in Childhood (MIWGUC),(16) and the broader work underway by the Observational Medical
173 Outcomes Partnership (OMOP).(24–26) Future expansion of the dataset will be needed to ensure
174 coverage of international concepts and care structures.

175

176 In summary, this dataset provide a common language for describing clinical information for
177 childhood uveitis. This semantic interoperability will support data re-use, meaningful data storage,
178 and enable accurate and effective communication between healthcare professionals, researchers, and
179 healthcare information technology systems.

180

Medrxiv SNOMED-POIG

181 **Acknowledgments**

182 Members of the Paediatric Ocular Inflammation UNICORN Study Group

183 Professor Jugnoo Rahi, Professor of Ophthalmic Epidemiology, UCL GOS Institute of Child Health,

184 London, UK

185 Professor Andrew D Dick, Professor of Translational Health Sciences, Bristol Medical School,

186 University of Bristol, Bristol, UK

187 Professor Alastair Denniston, Professor of Ocular Inflammation, University of Birmingham, UK

188 Mr Damien C.M. Yeo, Consultant Ophthalmologist, Alder Hey Children's NHS Foundation Trust,

189 Liverpool

190 Mr Jose Gonzalez-Martin, Consultant Ophthalmologist, Alder Hey Children's NHS Foundation Trust,

191 Liverpool

192 Ms Eibhlin McLoone, Consultant Ophthalmologist, Belfast Royal Victoria Hospital NHS Foundation

193 Trust

194 Prof Rachel Pilling, Consultant Ophthalmologist, School of Optometry and Vision Science,

195 University of Bradford

196 Mr John Bradbury, Consultant Ophthalmologist, Bradford Teaching Hospitals NHS Foundation Trust,

197 Bradford Royal Infirmary

198 Prof Athimalaipet V Ramanan, Consultant Paediatric Rheumatologist, University Hospitals Bristol

199 NHS Foundation Trust

200 Ms Catherine Guly, Consultant Ophthalmologist, University Hospitals Bristol NHS Foundation Trust

201 Ms Brinda Muthusamy, Consultant Ophthalmologist, Cambridge University Hospital NHS

202 Foundation Trust

203 Mr Patrick Watts, Consultant Ophthalmologist, Cardiff and Vale University Health Board Hospitals

204 Ms Christine Twomey, Clinical Nurse Specialist, Great Ormond Street Hospital NHS Foundation

205 Trust

206 Ms Reshma Pattani, Specialist Optometrist, Great Ormond Street Hospital NHS Foundation Trust

Medrxiv SNOMED-POIG

- 207 Mr Clive Edelsten, Consultant Ophthalmologist, Great Ormond Street Hospital NHS Foundation
208 Trust
- 209 Mr Daniel Pharoah, Consultant Ophthalmologist, James Paget University Hospitals NHS Foundation
210 Trust
- 211 Mr Vernon Long, Leeds Teaching Hospitals NHS Trust, St. James's University Hospital
- 212 Mr Adam Bates, Consultant Ophthalmologist, Maidstone and Tunbridge Wells NHS Trust
- 213 Ms Elisabetta Scoppettuolo, Consultant Ophthalmologist, Maidstone and Tunbridge Wells NHS Trust
- 214 Prof Jane Ashworth, Consultant Ophthalmologist, Manchester University NHS Foundation Trust
- 215 Ms Laura Steeples, Consultant Ophthalmologist, Manchester University NHS Foundation Trust
- 216 Mr Harry Petrushkin, Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust
217 and Great Ormond Street Hospital NHS Foundation Trust
- 218 Ms Dhanes Thomas, Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust
- 219 Mr Alan John Connor, Consultant Ophthalmologist, Newcastle Upon Tyne Hospitals NHS
220 Foundation Trust
- 221 Dr Una O'Colmain, Consultant Ophthalmologist, Ninewells Hospital, Tayside Scotland NHS Board
- 222 Mr Anas Injarie, Consultant Ophthalmologist, Norfolk and Norwich University Hospitals NHS
223 Foundation Trust
- 224 Mr Narman Puvanachandra, Consultant Ophthalmologist, Norfolk and Norwich University Hospitals
225 NHS Foundation Trust
- 226 Ms Archana Pradeep, Consultant Ophthalmologist, Nottingham University Hospitals NHS Trust
- 227 Dr Kishore Warrior, Consultant Paediatric Rheumatologist, Nottingham University Hospitals NHS
228 Trust
- 229 Ms Srilakshmi Sharma, Consultant Ophthalmologist, Oxford University Hospitals NHS Foundation
230 Trust
- 231 Dr Conrad Schmoll, Consultant Ophthalmologist, Princess Alexandra Eye Pavilion / Royal Hospital
232 for Children and Young People, Edinburgh, Lothian NHS Board
- 233 Dr Eoghan Millar, Consultant Ophthalmologist, Royal Children's Hospital, NHS Greater Glasgow
234 and Clyde

Medrxiv SNOMED-POIG

235 Mrs Kate Bush, Consultant Ophthalmologist, Royal Bournemouth Christchurch Hospitals NHS
236 Foundation Trust

237 Mr M. Ashwin Reddy, Consultant Ophthalmologist, Royal London Hospital, Barts Health NHS Trust

238 Ms Jessy Choi, Consultant Ophthalmologist, Sheffield Children's Hospitals NHS Foundation Trust,
239 and Sheffield Teaching Hospitals NHS Foundation Trust

240 Ms Gisella Cooper, Clinical Nurse Specialist, Sheffield Children's Hospitals NHS Foundation Trust,
241 and Sheffield Teaching Hospitals NHS Foundation Trust

242 Ms Kristina May, Consultant Ophthalmologist, University Hospital Southampton NHS Foundation
243 Trust, Southampton General Hospital

244 Mr Ed Hughes, Consultant Ophthalmologist, Sussex Eye Hospital, University Hospitals Sussex NHS
245 Foundation Trust

246 Ms Ailsa Ritchie, Consultant Ophthalmologist, St Thomas' Hospital, Guys and St Thomas' NHS
247 Trust

248 The authors would also like to thank the wider Paediatric Ocular Inflammation Group
249 (<https://www.ucl.ac.uk/child-health/poig>) for their support for the study.

250

251 **Conflicts of Interest**

252 The authors declare that the research was conducted in the absence of any commercial or financial
253 relationships that could be construed as a potential conflict of interest.

254 **Author Contributions**

255 All authors contributed to the development of the dataset. ALS and SK mapped the data elements to
256 international terminologies. SK wrote the manuscript. All authors read and approved the final
257 manuscript.

258 **Funding**

259 AL Solebo and S Kellett are supported by an NIHR Clinician Scientist award CS-2018-18-ST2-005.
260 This work is part supported by a Wellcome Grant 204841/Z/16/Z. This work was undertaken at UCL
261 Institute of Child Health / Great Ormond Street Hospital for children which received a proportion of
262 funding from the Department of Health's NIHR Biomedical Research Centers funding scheme.

Medrxiv SNOMED-POIG

263 **Availability of data and materials:**

264 Data elements, response options and value sets can be accessed via the supplemental documents and
265 institutional repository

266 **Ethics approval and consent to participate:**

267 No permissions were required to access any data used in this study.

268

269 **References**

- 270 1. Rahman N, Petrushkin H, Solebo AL. Paediatric autoimmune and autoinflammatory
271 conditions associated with uveitis. *Ther Adv Ophthalmol*. 2020 Jan 2;12:251584142096645.
- 272 2. Jones NP, Pradeep A, John B. Certification of Vision Impairment in Patients with Uveitis
273 Attending a Specialist Clinic. *Ocul Immunol Inflamm*. 2019 May 19;27(4):540–4.
- 274 3. Ferrara M, Eggenschwiler L, Stephenson A, Montieth A, Nakhoul N, Araùjo-Miranda R, et al.
275 The Challenge of Pediatric Uveitis: Tertiary Referral Center Experience in the United States.
276 *Ocul Immunol Inflamm*. 2019;27(3).
- 277 4. Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric
278 uveitis in english primary and referral centers. *Am J Ophthalmol*. 2003;135(5).
- 279 5. Haasnoot AMJW, Vernie LA, Rothova A, Doe P V.D., Los LI, Schaliij-Delfos NE, et al.
280 Impact of juvenile idiopathic arthritis associated uveitis in early adulthood. *PLoS One*.
281 2016;11(10).
- 282 6. Siiskonen M, Hirn I, Pesälä R, Hautala T, Ohtonen P, Hautala N. Prevalence, incidence and
283 epidemiology of childhood uveitis. *Acta Ophthalmol*. 2021 Mar 26;99(2).
- 284 7. Acharya NR, Tham VM, Esterberg E, Borkar DS, Parker J V., Vinoya AC, et al. Incidence and
285 prevalence of uveitis: Results from the Pacific Ocular Inflammation Study. *JAMA*
286 *Ophthalmol*. 2013;131(11).
- 287 8. Koay S yin, Johnson M, Xing W, Foot B, MacEwen C, Dahlmann-Noor A, et al. Childhood
288 uveitis not associated with juvenile idiopathic arthritis: a national survey of incidence,
289 management and visual outcomes. *Eye*. 2021 Sep 16;35(9):2573–8.

Medrxiv SNOMED-POIG

- 290 9. Solebo AL. Why Do We Treat? Defining Disease Control in Juvenile Idiopathic Arthritis–
291 Associated Uveitis. *J Rheumatol*. 2023 Jul 1;jrheum.2022-1336.
- 292 10. Rahman N, Petrushkin H, Solebo AL. Paediatric autoimmune and autoinflammatory
293 conditions associated with uveitis. *Ther Adv Ophthalmol*. 2020 Jan 2;12:251584142096645.
- 294 11. Fatoye F, Gebrye T, Odeyemi I. Real-world incidence and prevalence of low back pain using
295 routinely collected data. *Rheumatol Int*. 2019 Apr 8;39(4):619–26.
- 296 12. Schwab P, DuMont Schütte A, Dietz B, Bauer S. Clinical Predictive Models for COVID-19:
297 Systematic Study. *J Med Internet Res*. 2020 Oct 6;22(10):e21439.
- 298 13. Mc Cord KA, Al-Shahi Salman R, Treweek S, Gardner H, Strech D, Whiteley W, et al.
299 Routinely collected data for randomized trials: promises, barriers, and implications. *Trials*.
300 2018 Dec 11;19(1):29.
- 301 14. Solebo AL, Hysi P, Horvat-Gitsels LA, Rahi JS. Data saves lives: optimising routinely
302 collected clinical data for rare disease research. *Orphanet J Rare Dis*. 2023 Sep 11;18(1):285.
- 303 15. Solebo AL, Kellett S, Rahi J, Pattani R, Edelsten C, Dick AD, et al. Development of a
304 Nationally Agreed Core Clinical Dataset for Childhood Onset Uveitis. *Front Pediatr*. 2022 Jun
305 21;10.
- 306 16. Foeldvari I, Klotsche J, Simonini G, Edelsten C, Angeles-Han ST, Bangsgaard R, et al.
307 Proposal for a definition for response to treatment, inactive disease and damage for JIA
308 associated uveitis based on the validation of a uveitis related JIA outcome measures from the
309 Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC).
310 *Pediatric Rheumatology*. 2019 Dec 1;17(1):66.
- 311 17. Royal College of Ophthalmologists. [https://www.rcophth.ac.uk/wp-](https://www.rcophth.ac.uk/wp-content/uploads/2021/10/Uveitis-Data-Set-Oct-2018.pdf)
312 [content/uploads/2021/10/Uveitis-Data-Set-Oct-2018.pdf](https://www.rcophth.ac.uk/wp-content/uploads/2021/10/Uveitis-Data-Set-Oct-2018.pdf). Uveitis Dataset.
- 313 18. <https://www.snomed.org/> [Internet]. SNOMED CT.
- 314 19. Solebo AL, Rahi JS, Dick AD, Ramanan A V, Ashworth J, Edelsten C. Areas of agreement in
315 the management of childhood non-infectious chronic anterior uveitis in the UK. *British Journal*
316 *of Ophthalmology*. 2020 Jan;104(1):11–6.

Medrxiv SNOMED-POIG

- 317 20. National Institutes of Health (NIH). <https://www.commondataelements.ninds.nih.gov/glossary>.
318 Classifications of Data Elements for a Particular Disease.
- 319 21. <https://hl7.org/FHIR/> [Internet]. HL7 FHIR Release 5.
- 320 22. Arslanoglu Aydin E, Ozdel S, Cakar Ozdal P, Bagrul İ, Baglan E, Tuncez S, et al. Changing
321 face of non-infectious pediatric uveitis in the pre-pandemic and pandemic periods: a
322 comparison study. *Postgrad Med*. 2023 May 19;135(4):418–23.
- 323 23. Lafay C, Assad Z, Ouldali N, Quoc EB, Clement A, Durand C, et al. Increased Incidence of
324 Pediatric Uveitis Associated with the COVID-19 Pandemic Occurring Before COVID-19
325 Vaccine Implementation: A Time-Series Analysis. *J Pediatr*. 2023 Dec;263:113682.
- 326 24. Belenkaya R, Gurley MJ, Golozar A, Dymshyts D, Miller RT, Williams AE, et al. Extending
327 the OMOP Common Data Model and Standardized Vocabularies to Support Observational
328 Cancer Research. *JCO Clin Cancer Inform*. 2021 Dec;(5):12–20.
- 329 25. Klann JG, Joss MAH, Embree K, Murphy SN. Data model harmonization for the All Of Us
330 Research Program: Transforming i2b2 data into the OMOP common data model. *PLoS One*.
331 2019 Feb 19;14(2):e0212463.
- 332 26. Künnapu K, Ioannou S, Ligi K, Kolde R, Laur S, Vilo J, et al. Trajectories: a framework for
333 detecting temporal clinical event sequences from health data standardized to the Observational
334 Medical Outcomes Partnership (OMOP) Common Data Model. *JAMIA Open*. 2022 Jan
335 7;5(1).
336